SURESNES, France; SHANGHAI, PRC – 13 September, 2013 – Lucitanib (International Nonproprietary Name) is a kinase inhibitor which targets fibroblast growth factor receptor 1-2 (FGFR1-2), and vascular endothelial growth factor receptor-1-3 (VEGFR-1-3). This unique activity profile confers on lucitanib specific antitumor activity in FGFR1-2 dependent tumors and a strong antiangiogenic effect.
The 28th International Conference on Photonic, Electronic and Atomic Collisions (XXVIII ICPEAC) was successfully carried out in 24-30 July in Lanzhou, China. The conference was hosted by Institute of Modern Physics, Chinese Academy of Sciences (IMP), and more than 500 scientists and students from about 40 countries and/or regions participated the conference.?Five plenary lectures and more than 80 oral progress and special reports were arranged, nominated and decided by ICPEAC International General Committee, and more than 600 abstracts?were selected as poster presentation.
86-10-68597521 (day)
86-10-68597289 (night)
86-10-68511095 (day)
86-10-68512458 (night)
cas_en@cas.cn
52 Sanlihe Rd., Xicheng District,
Beijing, China (100864)